Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion

Circulation. 2008 May 27;117(21):2761-8. doi: 10.1161/CIRCULATIONAHA.107.755066. Epub 2008 May 19.

Abstract

Background: Opening of the mitochondrial permeability transition pore (mPTP) is a crucial event in lethal reperfusion injury. Phosphorylation (inhibition) of glycogen synthase kinase-3beta (GSK3beta) has been involved in cardioprotection. We investigated whether phosphorylated GSK3beta may protect the heart via the inhibition of mPTP opening during postconditioning.

Methods and results: Wild-type and transgenic GSK3beta-S9A mice (the cardiac GSK3beta activity of which cannot be inactivated) underwent 60 minutes of ischemia and 24 hours of reperfusion. At reperfusion, wild-type and GSK3beta-S9A mice received no intervention (control), postconditioning (3 cycles of 1 minute ischemia and 1 minute of reperfusion), the mPTP inhibitor cyclosporine A (CsA; 10 mg/kg IV), or the GSK3beta inhibitor SB216763 (SB21; 70 microg/kg IV). Infarct size was assessed by triphenyltetrazolium chloride staining. The resistance of the mPTP to opening after Ca(2+) loading was assessed by spectrofluorometry on mitochondria isolated from the area at risk. In wild-type mice, infarct size was significantly reduced by postconditioning, CsA, and SB21, averaging 39+/-2%, 35+/-5%, and 37+/-4%, respectively, versus 58+/-5% of the area at risk in control mice (P<0.05). In GSK3beta-S9A mice, only CsA, but not postconditioning or SB21, reduced infarct size. Postconditioning, CsA, and SB21 all improved the resistance of the mPTP in wild-type mice, but only CsA did so in GSK3beta-S9A mice.

Conclusions: These results suggest that S9-phosphorylation of GSK3beta is required for postconditioning and likely acts by inhibiting the opening of the mitochondrial permeability transition pore.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cyclosporine / pharmacology
  • Disease Models, Animal
  • Enzyme Inhibitors / pharmacology
  • Glycogen Synthase Kinase 3 / antagonists & inhibitors*
  • Glycogen Synthase Kinase 3 / genetics
  • Glycogen Synthase Kinase 3 / metabolism*
  • Glycogen Synthase Kinase 3 beta
  • Indoles / pharmacology
  • Ischemic Preconditioning, Myocardial*
  • Maleimides / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Microscopy, Electron
  • Mitochondria / enzymology
  • Mitochondria / ultrastructure
  • Mitochondrial Membrane Transport Proteins / antagonists & inhibitors
  • Mitochondrial Membrane Transport Proteins / metabolism*
  • Mitochondrial Permeability Transition Pore
  • Myocardial Infarction / prevention & control
  • Myocardial Reperfusion Injury / metabolism
  • Myocardial Reperfusion Injury / pathology
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocytes, Cardiac / enzymology
  • Myocytes, Cardiac / pathology
  • Myocytes, Cardiac / ultrastructure
  • Oxidative Phosphorylation
  • Phosphorylation

Substances

  • Enzyme Inhibitors
  • Indoles
  • Maleimides
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Permeability Transition Pore
  • SB 216763
  • Cyclosporine
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, mouse
  • Glycogen Synthase Kinase 3